Vinorelbine tartrate | CAS#125317-39-7 | CAS#71486-22-1 | Microtubulin Inhibitor

MedKoo Cat#: 100930 | Name: Vinorelbine tartrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vinorelbine is a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.

Chemical Structure

Vinorelbine tartrate

CAS#125317-39-7 (tartrate)

Theoretical Analysis

MedKoo Cat#: 100930

Name: Vinorelbine tartrate

CAS#: 125317-39-7 (tartrate)

Chemical Formula: C53H66N4O20

Exact Mass: 1078.4270

Molecular Weight: 1079.10

Elemental Analysis: C, 58.99; H, 6.16; N, 5.19; O, 29.65

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 180.00	Ready to ship
50mg	USD 285.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

125317-39-7 (tartrate) 105661-07-2 (tartrate 1:1) 71486-22-1 (free base)

Synonym

KW2307, KW-2307, KW 2307, vinorelbine tartrate, Navelbine, Biovelbin, Eunades

IUPAC/Chemical Name

methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate)

InChi Key

CILBMBUYJCWATM-PYGJLNRPSA-N

InChi Code

InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37-,38+,39+,42+,43+,44-,45-;2*1-,2-/m011/s1

SMILES Code

O=C(OC)[C@@]1([C@@]2(N(C3=C([C@@]24CCN5CC=C[C@@](CC)([C@H]1OC(C)=O)[C@@]45[H])C=C(C(OC)=C3)[C@]6(C[C@]7([H])C=C(CN(CC8=C6NC9=C8C=CC=C9)C7)CC)C(OC)=O)C)[H])O.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#TZC50930

QC Data

View QC data: current batch, Lot#TZC50930

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Vinorelbine (ditartrate) inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

In vitro activity:

To determine the mechanism of protection from the pro-apoptotic action of metronomic vinorelbine the balance of the anti-apoptotic Bcl-2 and pro-apoptotic protein Bax (Fig. 6A) was investigated. Bcl-2 and Bax are players of the intrinsic mitochondrial apoptotic pathway and a low Bcl-2/Bax ratio leads to apoptotic cell death through mitochondrial outer membrane permeabilization (MOMP). Moreover, Bcl-2 downregulation has previously been implicated in the cell death caused by vinorelbine. Ten nanomolar vinorelbine downregulated the anti-apoptotic protein Bcl-2 in normoxia by 32% (P<0.01) at 24 h. Severe hypoxia also decreased Bcl-2 protein by 46% (P<0.001) but 10 nM vinorelbine did not further reduce Bcl-2 under these conditions (Fig. 6B). Similar changes were seen in the Bcl-2/Bax ratio (Fig. 6C). In particular, 10 nM vinorelbine decreased the Bcl-2/Bax ratio by 30% (P<0.05) in normoxia at 24 h, which is consistent with induction of apoptosis. Severe hypoxia decreased the Bcl-2/Bax ratio by 42% (P<0.01) while 10 nM vinorelbine did not have an additional effect. Reference: Int J Oncol. 2015 Aug; 47(2): 455–464. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501653/

In vivo activity:

This study used a model previously described where JEG3 cells are xenografted subcutaneously into immune deficient (SCID) female mice and placental tumors allowed to form. Mice were then treated intravenously (via tail vein) with 1.25, 2.5 or 5 mg/kg vinorelbine, or vehicle control on days 6, 9 and 12 after xenograft inoculation. Compared to vehicle controls, vinorelbine at all doses significantly reduced xenograft volume 4 days after treatment (10 days after JEG3 inoculation) and each measured time point thereafter (12 and 14 days after inoculation) (Fig. 2A, B). Furthermore, vinorelbine treatment caused a significant, dose dependent reduction in xenograft tumor weight (harvested at the time of euthanasia) (Fig. 2C). There was a concordant dose dependent reduction in serum hCG from blood taken at the time of euthanasia. Significantly, at the top dose of vinorelbine (5 mg/kg) 6 out of 8 mice had a resolution of the tumor to the extent that no tumor could be found (Fig. 2C). Of these 6 mice, 5 had serum hCG levels below the detectable range of the assay (Fig. 2D). This suggests the possible complete absence of placental xenograft tumors in 5 mice. Reference: EBioMedicine. 2018 Mar; 29: 166–176. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925452/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	92.67
	Ethanol	100.0	92.67
	Water	100.0	92.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,079.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL. Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol. 2015 Aug;47(2):455-64. doi: 10.3892/ijo.2015.3059. Epub 2015 Jun 19. PMID: 26095084; PMCID: PMC4501653. 2. Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1. PMID: 21128224. 3. Hastie R, Lim E, Sluka P, Campbell L, Horne AW, Ellett L, Hannan NJ, Brownfoot F, Kaitu'u-Lino TJ, Tong S. Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine. 2018 Mar;29:166-176. doi: 10.1016/j.ebiom.2018.01.041. Epub 2018 Feb 2. PMID: 29429891; PMCID: PMC5925452. 4. Cui R, Yoshioka M, Takahashi F, Ishida H, Iwakami S, Takahashi K. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice. Anticancer Res. 2008 May-Jun;28(3A):1633-9. PMID: 18630520.

In vitro protocol:

In vivo protocol:

1. Hastie R, Lim E, Sluka P, Campbell L, Horne AW, Ellett L, Hannan NJ, Brownfoot F, Kaitu'u-Lino TJ, Tong S. Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine. 2018 Mar;29:166-176. doi: 10.1016/j.ebiom.2018.01.041. Epub 2018 Feb 2. PMID: 29429891; PMCID: PMC5925452. 2. Cui R, Yoshioka M, Takahashi F, Ishida H, Iwakami S, Takahashi K. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice. Anticancer Res. 2008 May-Jun;28(3A):1633-9. PMID: 18630520.

1: Al-Omar A, Asadi M, Mert U, Muftuoglu C, Karakus HS, Goksel T, Caner A. Effects of Vinorelbine on M2 Macrophages in Non-Small Cell Lung Cancer. Int J Mol Sci. 2025 Mar 3;26(5):2252. doi: 10.3390/ijms26052252. PMID: 40076874; PMCID: PMC11900078. 2: Cao M, Wang R, Cheng X, Yu H, Tong Q, Yao Y. Patient-Derived Organoids for Guiding Neoadjuvant Chemotherapy in Bilateral Primary Breast Cancer: A Case Report. Onco Targets Ther. 2025 Mar 6;18:319-324. doi: 10.2147/OTT.S484293. PMID: 40066235; PMCID: PMC11892363. 3: Yang Z, Fu WD, Gu HY, Ding JL, Guo GL. A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer. Cancer Manag Res. 2025 Mar 4;17:441-460. doi: 10.2147/CMAR.S486211. PMID: 40060705; PMCID: PMC11890310. 4: Bisogno G, Chisholm J, Hladun R, De Salvo GL, Guerin F, Casanova M, Mandeville H, Alaggio R, Coppadoro B, Orbach D, Ferrari A, van Rijn R, Defachelles AS, Ben-Arush M, Glosli H, Cesen M, Merks JHM, Minard-Colin V. Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial. J Clin Oncol. 2025 Mar 7:JCO2402850. doi: 10.1200/JCO-24-02850. Epub ahead of print. PMID: 40053891. 5: Muster J, Alt NJ, Edelmann M, Anczykowski MZ, Zwerenz CM, Schirmer MA, Overbeck TR, Braulke F, Guhlich M, Shafie RE, Rieken S, Leu M, Dröge LH. Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT. Strahlenther Onkol. 2025 Mar 6. doi: 10.1007/s00066-025-02377-0. Epub ahead of print. PMID: 40050448. 6: Kicken MP, Deenen MJ, van der Wekken AJ, van den Borne BEEM, van den Heuvel MM, Ter Heine R. Opportunities for Precision Dosing of Cytotoxic Drugs in Non- Small Cell Lung Cancer: Bridging the Gap in Precision Medicine. Clin Pharmacokinet. 2025 Mar 5. doi: 10.1007/s40262-025-01492-6. Epub ahead of print. PMID: 40045151. 7: Xinzhu XU, Guo L, Zheng K, Ma Y, Lin S, He Y, Sheng W, Xu S, Qiu F. 副干酪乳酪杆菌E6通过其代谢物改善长春瑞滨诱导的斑马鱼免疫抑制 [Lacticaseibacillus paracasei E6 improves vinorelbine-induced immunosuppression in zebrafish through its metabolites acetic acid and propionic acid]. Nan Fang Yi Ke Da Xue Xue Bao. 2025 Feb 20;45(2):331-339. Chinese. doi: 10.12122/j.issn.1673-4254.2025.02.14. PMID: 40031977; PMCID: PMC11875848. 8: Datopotamab deruxtecan (Datroway) for advanced breast cancer. Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-e42. doi: 10.58347/tml.2025.1723e. PMID: 40009990. 9: Bandini A, Banchi M, Orlandi P, Vaglini F, Alì G, Fontanini G, Ottani A, Giuliani D, Vandini E, Francia G, Carli M, Scarselli M, Bocci G. Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo. J Clin Med. 2025 Feb 11;14(4):1165. doi: 10.3390/jcm14041165. PMID: 40004697; PMCID: PMC11856147. 10: Ho IW, Tseng YR, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC, Lai JI. Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. J Cancer. 2025 Feb 11;16(5):1726-1735. doi: 10.7150/jca.105199. PMID: 39991566; PMCID: PMC11843244. 11: Shreim M, Salhab A, Abu Sabha M, Karama A. Neutrophilic leucocytosis as a presenting sign of primary gastric Hodgkin's lymphoma. BMJ Case Rep. 2025 Feb 20;18(2):e263501. doi: 10.1136/bcr-2024-263501. PMID: 39979036. 12: Advanced breast cancer: diagnosis and treatment. London: National Institute for Health and Care Excellence (NICE); 2025 Feb 19. PMID: 31999418. 13: Amodeo R, Morosi L, Meroni M, Bello E, Timo S, Frapolli R, D'Incalci M, Lupi M. Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells. Am J Cancer Res. 2025 Jan 15;15(1):271-285. doi: 10.62347/ODWL5634. PMID: 39949944; PMCID: PMC11815374. 14: Lo Greco MC, Marano G, La Rocca M, Acquaviva G, Milazzotto R, Liardo RLE, Basile A, Foti PV, Palmucci S, David E, Parisi S, Pontoriero A, Pergolizzi S, Spatola C. Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review. Cancers (Basel). 2025 Jan 27;17(3):420. doi: 10.3390/cancers17030420. PMID: 39941789; PMCID: PMC11815860. 15: Khanmammadov N, Doğan I, Khishigsuren B, Azizy A, Saip P, Aydiner A. Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine. Medicine (Baltimore). 2025 Feb 7;104(6):e41468. doi: 10.1097/MD.0000000000041468. PMID: 39928785; PMCID: PMC11813031. 16: Su W, Li J. Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years. Anticancer Drugs. 2025 Feb 14. doi: 10.1097/CAD.0000000000001699. Epub ahead of print. PMID: 39908219. 17: Fortunati D, Montanari A, Viso M, Felizzia G, Warriner E, Bosaleh A, Rizzi A, Solernou V, López Marti J, Sobrero V, Flores P, Cacciavillano W, Schwartz M, Racca G, Rose A. Extra-renal non-cerebral malignant rhabdoid tumor in children: does maintenance chemotherapy play a role in survival? Medicina (B Aires). 2025;85(1):101-111. English. PMID: 39900054. 18: Sun L, Wang J, Yu H, Zhu X, Zhang J, Hu J, Yan Y, Zhang X, Zhu Y, Jiang G, Ding M, Zhang P, Zhang L. Selective inhibition of TGF-β-induced epithelial- mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma. Commun Biol. 2025 Feb 1;8(1):152. doi: 10.1038/s42003-025-07595-x. PMID: 39893253; PMCID: PMC11787392. 19: Riestra AC, Urretavizcaya M, Ferro Uriguen A, Olariaga Sarasola O, Iglesias A, Camba Y, Asensio Bermejo A, Tames MJ. Monitoring of occupational exposure to hazardous medicinal products in robotic compounding. Eur J Hosp Pharm. 2025 Jan 31:ejhpharm-2024-004294. doi: 10.1136/ejhpharm-2024-004294. Epub ahead of print. PMID: 39890433. 20: Zhang Z, Zheng K, Zhang Z, Cao L, Lin L, Sun W, Qiu F. Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. Microb Cell Fact. 2025 Jan 30;24(1):34. doi: 10.1186/s12934-025-02662-8. PMID: 39885499; PMCID: PMC11780890.